ProCE Banner Activity

Immuno-Oncology in Myeloma: New Indications and Approvals

Slideset

Slides featuring expert perspectives on multiple myeloma new therapy indications and optimizing integration into current algorithms.

Released: June 01, 2023

Share

Faculty

Joseph Mikhael

Joseph Mikhael, MD, MEd, FRCPC, FACP

Professor
Applied Cancer Research and Drug Discovery 
Translational Genomics Research Institute 
Phoenix, Arizona
Chief Medical Officer
International Myeloma Foundation 
HonorHealth Research Institute 
Scottsdale, Arizona

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Noopur Raje

Noopur Raje, MD

Director
Center for Multiple Myeloma
Rita Kelly Chair in Oncology
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Karyopharm Therapeutics, Legend Biotech USA Inc., and Pfizer Inc.

AbbVie Inc.

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics Inc.

Legend Biotech USA Inc.

Pfizer, Inc.